Insider Selling: Raptor Pharmaceutical Corp. CEO Sells 25,000 Shares of Stock (RPTP)
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) CEO Christopher Starr unloaded 25,000 shares of the company’s stock on the open market in a transaction dated Monday, September 16th. The stock was sold at an average price of $14.21, for a total transaction of $355,250.00. Following the completion of the transaction, the chief executive officer now directly owns 699,370 shares in the company. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $12.00 to $14.00 in a research note to investors on Friday, August 9th. Separately, analysts at JMP Securities raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $13.00 to $15.00 in a research note to investors on Friday, August 9th. Finally, analysts at Canaccord Genuity raised their price target on shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) from $14.00 to $16.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Raptor Pharmaceutical Corp. presently has an average rating of “Buy” and a consensus price target of $12.17.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded up 0.35% on Wednesday, hitting $14.35. The stock had a trading volume of 600,354 shares. Raptor Pharmaceutical Corp. has a 1-year low of $4.35 and a 1-year high of $14.90. The stock has a 50-day moving average of $12.5 and a 200-day moving average of $8.5. The company’s market cap is $856.1 million.
Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its earnings data on Thursday, August 8th. The company reported ($0.30) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.30). Analysts expect that Raptor Pharmaceutical Corp. will post $-1.24 EPS for the current fiscal year.
Raptor Pharmaceuticals Corp. (NASDAQ:RPTP), formerly TorreyPines Therapeutics, Inc, is an early development-stage Company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.